For the quarter ending 2025-11-30.
| Income Statement | 2025-11-30 | 2025-08-31 | ||
|---|---|---|---|---|
| General and administrative | 1,799 | 1,713 | ||
| Research and development | 3,302 | 3,232 | ||
| Legal settlement loss | 16,587 | - | ||
| Total operating expenses | 21,688 | 4,945 | ||
| Operating (loss) gain | -21,688 | -4,945 | ||
| Interest income | 57 | 94 | ||
| Interest on convertible notes | 644 | 676 | ||
| Standby equity purchase agreement commitment fee | 325 | - | ||
| Finance charges | 7 | 13 | ||
| Total interest and other expenses | -919 | -595 | ||
| (loss) gain before income taxes | -22,607 | -5,540 | ||
| Income tax benefit | 0 | 0 | ||
| Net (loss) income | -22,607 | -5,540 | ||
| Basic EPS | -0.02 | 0 | ||
| Diluted EPS | -0.02 | 0 | ||
| Basic Average Shares | 1,261,016,000 | 1,252,551,000 | ||
| Diluted Average Shares | 1,261,016,000 | 1,252,551,000 | ||
CytoDyn Inc. (CYDY)
CytoDyn Inc. (CYDY)